Close

Oppenheimer Assumes Acceleron Pharma (XLRN) at Outperform

April 22, 2019 3:09 AM EDT Send to a Friend
Oppenheimer analyst Leland Gershell assumes coverage on Acceleron Pharma (NASDAQ: XLRN) with a Outperform rating and a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login